Abstract: ob＜x＞jective To systematically evaluate the efficacy of atorvastatin combined with trimetazidine and atorvastatin alone in the treatment of patients with chronic heart failure. Methods Using domestic and foreign databases such as PubMed and China Biomedical Literature Database as the data source.Trimetazidine, Atorvastatin and heart failure were the main Chinese and English keywords. According to the set inclusion and exclusion criteria, the relevant literature was included. The search was limited to the databa＜x＞se establishment until October 2019. After the data was extracted, the R test me＜x＞ta-analysis package was used to perform me＜x＞ta-analysis on the included test data. Results This meta-analysis was finally included in 13 studies, with a total of 1265 patients. The results showed that the atorvastatin combined with the trimetazidine group compared with the control group, RR 1.20, 95% CI (1.13, 1.28), P <0.00001; increased left ventricular ejection fraction (Left ventricular ejection fraction, LVEF), SMD = 1.67, 95% CI (1.23, 2.11), P <0.00001; reduced left ventricular end-diastolic dimension, LVEFD, SMD = -1.13, 95% CI (-1.42, -0.83 ), P <0.00001; reduction of left ventricular end systolic diameter (LVESD), SMD =-1.80, 95% CI (-2.04, -1.55), P <0.00001; increase 6 min movement distance, SMD = 1.14 ,95% CI (0.98, 1.30), P <0.00001; Lower brain natriuretic peptide (BNP), SMD = -1.35, 95% CI (-1.71, -01.00), P <0.00001. Conclusion Compared with atorvastatin alone and conventional therapy, atorvastatin combined with trimetazidine plus conventional therapy can improve the overall clinical effectiveness of heart failure patients and improve cardiac function indicators. However, due to the limited quality and limited number of studies included in this systematic review, it is necessary to continue to conduct large-sample, high-quality randomized controlled trials to provide more evidence-based evidence to better guide clinical medication.